Literature DB >> 7932043

The stability of bFGF against thermal denaturation.

S Vemuri1, I Beylin, V Sluzky, P Stratton, G Eberlein, Y J Wang.   

Abstract

The influence of sulphated ligand and pH on thermal denaturation of basic fibroblast growth factor (bFGF) was investigated by differential scanning calorimetry (DSC), and verified by fluorescence spectrophotometry. Purity of bFGF before and after heat denaturation was assessed by SDS-PAGE analysis. In DSC studies the samples were heated to 95 degrees C. The midpoint of the temperature change in the thermogram was designated as Tm. Sulphated ligand experiments were undertaken in potassium phosphate (pH 6.5) and sodium acetate buffers. Control thermograms (with no ligand) showed a Tm at 59 degrees C in potassium phosphate buffer. Higher Tm values were noted as sulphated ligand concentration was increased. Similarly when heparin was added, the Tm moved to a higher temperature. A ratio as low as 0.3:1 of heparin to bFGF, increased the Tm to 90 degrees C, which is a 31 degrees C shift in Tm. The effect of pH on thermal denaturation of bFGF was studied in a citrate-phosphate-borate buffer system. A shift in Tm from 46 to 65 degrees C was observed as the pH is changed from 4 to 8. Changes in protein conformation as a function of pH were monitored by fluorescence spectroscopy. It was found that a pH range from 5 to 9 is optimal for the stability of bFGF formulations. In a stability study it was noted that heparin protected bFGF from thermal denaturation only at high temperature.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7932043     DOI: 10.1111/j.2042-7158.1994.tb03831.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  8 in total

1.  Fibroblast growth factor 2 dimer with superagonist in vitro activity improves granulation tissue formation during wound healing.

Authors:  Caitlin G Decker; Yu Wang; Samantha J Paluck; Lu Shen; Joseph A Loo; Alex J Levine; Lloyd S Miller; Heather D Maynard
Journal:  Biomaterials       Date:  2015-12-15       Impact factor: 12.479

2.  Fibroblast growth factor 2 induced proliferation in osteoblasts and bone marrow stromal cells: a whole cell model.

Authors:  Melissa A Dupree; Solomon R Pollack; Elliot M Levine; Cato T Laurencin
Journal:  Biophys J       Date:  2006-07-21       Impact factor: 4.033

3.  The effects of excipients on protein aggregation during agitation: an interfacial shear rheology study.

Authors:  Lu Liu; Wei Qi; Daniel K Schwartz; Theodore W Randolph; John F Carpenter
Journal:  J Pharm Sci       Date:  2013-05-27       Impact factor: 3.534

4.  Cell-Demanded VEGF Release via Nanocapsules Elicits Different Receptor Activation Dynamics and Enhanced Angiogenesis.

Authors:  Suwei Zhu; Tatiana Segura
Journal:  Ann Biomed Eng       Date:  2016-03-03       Impact factor: 3.934

5.  Susceptibility towards intramolecular disulphide-bond formation affects conformational stability and folding of human basic fibroblast growth factor.

Authors:  D Estapé; J van den Heuvel; U Rinas
Journal:  Biochem J       Date:  1998-10-15       Impact factor: 3.857

6.  Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors.

Authors:  Mateusz Adam Krzyscik; Malgorzata Zakrzewska; Vigdis Sørensen; Aleksandra Sokolowska-Wedzina; Michal Lobocki; Karolina Weronika Swiderska; Daniel Krowarsch; Antoni Wiedlocha; Jacek Otlewski
Journal:  ACS Omega       Date:  2017-07-21

7.  Heparin-conjugated collagen as a potent growth factor-localizing and stabilizing scaffold for regenerative medicine.

Authors:  Yasuhiro Ikegami; Hideyuki Mizumachi; Kozue Yoshida; Hiroyuki Ijima
Journal:  Regen Ther       Date:  2020-11-01       Impact factor: 3.419

8.  Heparinized Gelatin-Based Hydrogels for Differentiation of Induced Pluripotent Stem Cells.

Authors:  Matthew R Arkenberg; Karl Koehler; Chien-Chi Lin
Journal:  Biomacromolecules       Date:  2022-09-08       Impact factor: 6.978

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.